See the DrugPatentWatch profile for Bosentan
What is Bosentan 62.5 mg?
Bosentan 62.5 mg is a medication used to treat pulmonary arterial hypertension (PAH) [1]. It is a dual endothelin receptor antagonist, meaning it blocks the action of endothelin-1, a substance that can narrow blood vessels [1]. By blocking these receptors, bosentan helps to widen the blood vessels in the lungs, reducing blood pressure and improving the ability to exercise [1].
When is Bosentan 62.5 mg typically prescribed?
Bosentan 62.5 mg is generally prescribed as a starting dose for patients with pulmonary arterial hypertension [1]. The dosage is often gradually increased to a maintenance dose of 125 mg twice daily, depending on individual patient response and tolerability [1].
How does Bosentan work to treat PAH?
Bosentan works by antagonizing both endothelin A (ETA) and endothelin B (ETB) receptors [1]. Endothelin-1 is a potent vasoconstrictor and also stimulates smooth muscle cell proliferation. By blocking its receptors, bosentan leads to vasodilation in the pulmonary arteries and may inhibit vascular remodeling, thereby reducing pulmonary artery pressure and resistance [1].
What are the potential side effects of Bosentan?
Common side effects of bosentan can include swelling (edema), headache, flushing, nausea, and changes in liver function tests [1]. The drug also carries a risk of liver damage, which is why regular monitoring of liver enzymes is crucial during treatment [1].
Are there any alternatives to Bosentan for PAH?
Yes, there are other medications available for treating pulmonary arterial hypertension. These include other endothelin receptor antagonists like ambrisentan and macitentan, as well as phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil) and prostacyclin analogues (e.g., epoprostenol, treprostinil) [2]. The choice of treatment depends on the severity of the disease, individual patient factors, and potential drug interactions [2].
What is the patent status for Bosentan?
The original patents for bosentan have expired, allowing for the development and marketing of generic versions of the drug [3]. DrugPatentWatch.com tracks patent information for pharmaceuticals, including expirations and any associated litigation or exclusivity periods [3].
What are the risks associated with Bosentan treatment?
Beyond the potential side effects, bosentan carries specific risks. It is contraindicated in pregnant women due to the risk of birth defects and is only available through a restricted distribution program (the Bosentan REMS program) to mitigate these risks [1]. Patients must also undergo regular liver function monitoring due to the possibility of hepatotoxicity [1].
Sources
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020741s012,021971s006lbl.pdf
2. https://www.uptodate.com/contents/treatment-of-pulmonary-arterial-hypertension-in-adults-beyond-first-line-therapy
3. https://drugpatentwatch.com/